Cheapest Mounjaro Side Effects vs Wegovy - UK Price

Our Pricing

Comparing Mounjaro Side Effects vs Other Options

Published on: June 03, 2026

When researching mounjaro side effects vs wegovy uk options, understanding the tolerability profile of each treatment helps you make an informed choice. At Cured Pharmacy, our UK-registered clinical team assesses your medical history to recommend the weight loss treatment with the most suitable side effect profile for your individual circumstances, with Mounjaro available from £124.99 following consultation.

Understanding Mounjaro Side Effects vs Wegovy and Saxenda

Mounjaro (tirzepatide) is a dual GIP/GLP-1 receptor agonist, whilst Wegovy and Saxenda both contain semaglutide and liraglutide respectively — single GLP-1 receptor agonists [1]. This mechanistic difference influences both efficacy and side effect profiles. All three medications work by slowing gastric emptying and reducing appetite, which inherently produces gastrointestinal effects in most patients during initial treatment phases.

In the SURPASS-2 head-to-head trial comparing tirzepatide directly with semaglutide, both medications showed similar rates of nausea (17-22% for tirzepatide vs 18% for semaglutide 1mg), though tirzepatide demonstrated slightly higher rates of diarrhoea and vomiting at maximum doses [1][2]. However, discontinuation rates due to adverse events were comparable between treatments, suggesting similar overall tolerability when dose escalation follows recommended schedules.

The severity and duration of side effects typically correlate with how quickly the dose is increased. UK prescribers follow MHRA-approved titration schedules specifically designed to minimise gastrointestinal symptoms whilst allowing your body to adapt to each medication's mechanism of action [3].

Common Gastrointestinal Side Effects: A Detailed Comparison

Nausea remains the most frequently reported side effect across all GLP-1 receptor agonists. In clinical trials, approximately 20-30% of patients on Mounjaro experienced nausea, compared with 18-44% on Wegovy depending on dose, and 39% on Saxenda [1][2][4]. Crucially, nausea typically peaks during the first 4-8 weeks of treatment and diminishes significantly as your body adapts to the medication.

Diarrhoea affects approximately 20% of Mounjaro users, 30% of Wegovy users, and 21% of Saxenda users in clinical trials [1][2][4]. The dual-agonist mechanism of tirzepatide may produce slightly different bowel movement patterns compared to single-pathway GLP-1 agonists, though individual variation is substantial. Most patients find that maintaining adequate hydration and adjusting dietary fibre intake helps manage these symptoms effectively.

Vomiting occurs less frequently than nausea but follows similar patterns — affecting 8-10% of Mounjaro users, 9-24% of Wegovy users depending on dose, and 14% of Saxenda users [1][2][4]. If vomiting becomes persistent or severe, your UK prescriber may recommend temporarily pausing dose escalation or, in rare cases, switching to an alternative treatment with a different mechanism.

Managing Gastrointestinal Symptoms

Our clinical team at Cured Pharmacy provides detailed guidance on symptom management strategies. Eating smaller, more frequent meals, avoiding high-fat foods immediately after injection, and staying well-hydrated significantly reduce the severity of gastrointestinal effects for most patients. Injecting at bedtime rather than morning may also help some individuals sleep through peak nausea periods, which typically occur 1-3 days post-injection with weekly formulations.

Mounjaro Side Effects vs Orlistat-Based Treatments

Orlistat (available as prescription-strength Xenical or lower-dose Alli and Orlos) works through an entirely different mechanism — blocking fat absorption in the intestines rather than affecting appetite hormones [5]. This produces a distinctly different side effect profile that some patients find more challenging to manage in daily life.

The primary side effects of orlistat are gastrointestinal and directly related to its mechanism: oily stools, faecal urgency, increased flatulence, and potential faecal incontinence if dietary fat intake isn't carefully controlled [5]. These effects occur in up to 20-30% of users and persist throughout treatment whenever dietary fat exceeds recommended limits, unlike GLP-1 medications where side effects typically diminish over time.

In contrast, Mounjaro and other GLP-1 receptor agonists produce transient nausea and altered bowel habits that generally improve after the initial titration period [1][2]. Many patients find injectable GLP-1 treatments more socially manageable than orlistat, though orlistat remains an effective option for those who cannot tolerate injections or have contraindications to GLP-1 therapy. Your UK prescriber will discuss which side effect profile aligns better with your lifestyle and medical history.

Less Common But Important Side Effects Across Treatments

Beyond gastrointestinal effects, all GLP-1 receptor agonists including Mounjaro, Wegovy, and Saxenda carry a boxed warning regarding potential thyroid C-cell tumours, based on rodent studies [1][2][4]. Whilst no causal relationship has been established in humans during extensive clinical use, these medications are contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Pancreatitis represents another rare but serious potential adverse event, occurring in less than 1% of patients across GLP-1 trials [1][2]. Symptoms include severe, persistent abdominal pain radiating to the back, often accompanied by nausea and vomiting. If you experience these symptoms whilst on treatment, you should seek immediate medical attention and discontinue the medication pending clinical assessment.

Hypoglycaemia risk remains low with GLP-1 monotherapy but increases if you're also taking insulin or sulfonylureas for diabetes management [3]. Mounjaro's dual mechanism may produce slightly different glucose-lowering patterns compared to single-pathway agonists, though clinical trials showed similar overall hypoglycaemia rates when used without concomitant glucose-lowering medications [1].

Injection Site Reactions

Local injection site reactions — including redness, itching, or mild swelling — occur in approximately 2-5% of patients using any injectable weight loss treatment [1][2][4]. These reactions are typically mild and resolve within days. Rotating injection sites between abdomen, thigh, and upper arm, and ensuring the medication reaches room temperature before injection, minimises this risk. Saxenda's daily injection schedule may produce slightly higher cumulative site reaction rates compared to weekly Mounjaro or Wegovy injections.

Discontinuation Rates: What Clinical Trials Reveal

Treatment discontinuation due to adverse events provides crucial insight into real-world tolerability. In the SURPASS trials, 4.3-6.2% of Mounjaro users discontinued treatment due to side effects, compared with 4.5% in the semaglutide comparator arm [1]. The STEP trials showed 4.5-7.0% discontinuation rates for Wegovy depending on dose [2], whilst Saxenda trials reported approximately 6.4% discontinuation due to adverse events [4].

These similar discontinuation rates across different GLP-1 mechanisms suggest that individual patient factors — including genetic variations in drug metabolism, baseline gastrointestinal sensitivity, and psychological tolerance for temporary discomfort — matter more than the specific medication chosen. This is why personalised clinical assessment by a UK prescriber is essential rather than simply selecting the treatment with the theoretically 'mildest' side effect profile.

At Cured Pharmacy, our superintendent pharmacist Tarun Kumar (GPhC 2233073) and clinical team review your complete medical history, current medications, and previous experiences with gastrointestinal medications to recommend the treatment most likely to suit your individual tolerance profile. Follow-up support throughout your treatment journey allows dose adjustments if initial side effects prove more challenging than anticipated.

Making an Informed Choice: Balancing Efficacy and Tolerability

Whilst side effect profiles matter, they should be considered alongside efficacy data when choosing between treatments. Mounjaro demonstrated superior weight loss compared to semaglutide in head-to-head trials — with average reductions of 22.5% body weight on the highest dose versus 14.9% with semaglutide 1mg over 72 weeks [1] — despite similar side effect rates. This suggests that for many patients, the marginally higher efficacy justifies tolerating similar gastrointestinal effects.

However, individual circumstances vary considerably. Patients with pre-existing irritable bowel syndrome, inflammatory bowel disease, or severe gastroparesis may experience amplified gastrointestinal symptoms with any GLP-1 medication and might benefit from starting with lower-dose options or considering orlistat despite its different side effect challenges [3][5]. Conversely, patients with diabetes requiring robust glucose control alongside weight loss may particularly benefit from tirzepatide's dual mechanism despite its side effect profile.

Your UK prescriber conducts a thorough assessment considering your BMI, comorbidities, medication history, lifestyle factors, and treatment goals before recommending a specific option. All prescription weight loss treatments available through Cured Pharmacy — including Mounjaro from £124.99 Wegovy, Saxenda, and orlistat-based options — require this clinical consultation to ensure safe, appropriate prescribing tailored to your individual medical profile and side effect tolerance.

Starting Your Assessment at Cured Pharmacy

Our free online consultation takes under 3 minutes and allows our UK-registered prescribers to assess which weight loss treatment offers the optimal balance of efficacy and tolerability for your circumstances. With transparent upfront pricing, 100% discreet packaging, and ongoing clinical support throughout your treatment journey, Cured Pharmacy provides comprehensive care that extends beyond simply dispensing medication. Start your assessment today to discuss whether Mounjaro or an alternative option best suits your individual needs and side effect tolerance.

Jump to your dose (first-order price, 4-week pen):

Has the price of Mounjaro gone up?

Yes. From 1 September 2025, Eli Lilly raised the UK list price of Mounjaro, so pharmacies now pay more for every pen. The Pharmaceutical Journal reports that the cost to pharmacies moved from a range of £92 to £122 a pen to £133 for the 2.5mg pen and £330 for the 12.5mg and 15mg pens. For the highest dose, RTÉ reports that Lilly put the monthly price at £330, up from £122, which is a rise of about 170%.

The increase applies to private prescriptions. The Pharmaceutical Journal reports that NHS commissioning of tirzepatide is unaffected by the change in list price. Lilly confirmed the change on 15 August 2025.

Lilly sets the list price, but each pharmacy sets its own price and may receive rebates, which is why the same pen can cost different amounts.

Our current prices: on your first order with code Weightlossnew, Mounjaro is £124.99 at 2.5mg, £159 at 5mg and £267 at 15mg, with your consultation and delivery included. Prices checked 12 November 2026. See every dose.

Could it change again? Pharmacy prices can change at any time, so every price on this page carries the date it was checked, and we review the page again by 12 May 2027.

Mounjaro prices by dose and related guides

Every Mounjaro strength has its own price page, and each guide below answers one question in more detail. Prices shown are the first-order price with code Weightlossnew, checked 12 November 2026, and include your consultation and delivery.

Reviewed by

Tarun Kumar, Superintendent and Prescribing Pharmacist

GPhC registration 2233073. Pharmacy graduate of Aston University (2022) with a community pharmacy background, and co-founder of Cured Pharmacy (GPhC 9012511). Meet our clinical team · Check the GPhC register

Page last reviewed 12 November 2026. Next review: 12 May 2027.

Scientific References

1. Frías, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519 [accessed 13 August 2026]
2. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
3. Medicines and Healthcare products Regulatory Agency. (2023). Mounjaro 2.5 mg solution for injection in pre-filled pen: Summary of Product Characteristics. GOV.UK. https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency [accessed 13 August 2026]
4. Pi-Sunyer, X., Astrup, A., Fujioka, K., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892 [accessed 13 August 2026]
5. Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004). XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care, 27(1), 155–161. https://doi.org/10.2337/diacare.27.1.155 [accessed 13 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.
9. Pharmaceutical Journal. (2025). Reimbursement for NHS Mounjaro dispensing confirmed for September 2025. https://pharmaceutical-journal.com/article/news/reimbursement-for-nhs-mounjaro-dispensing-confirmed-for-september-2025 Accessed 12 November 2026.
10. Pharmaceutical Journal. (2025). UK's biggest online pharmacy freezes Mounjaro price amid reports of 'stockpiling'. https://pharmaceutical-journal.com/article/news/uks-biggest-online-pharmacy-freezes-mounjaro-price-amid-reports-of-stockpiling Accessed 12 November 2026.
11. RTÉ. (2025). Lilly to hike UK price of Mounjaro weight-loss drug by 170%. https://www.rte.ie/news/business/2025/0814/1528531-lilly-to-hike-uk-price-of-mounjaro-weight-loss-drug-by-170 Accessed 12 November 2026.
12. Eli Lilly and Company Limited. Mounjaro KwikPen solution for injection in pre-filled pen: Summary of Product Characteristics. electronic Medicines Compendium (emc). https://www.medicines.org.uk/emc/product/15484/smpc Accessed 12 November 2026.
13. National Institute for Health and Care Excellence. (2024). Tirzepatide for managing overweight and obesity [TA1026]. NICE. https://www.nice.org.uk/guidance/ta1026 Accessed 12 November 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.